Alkylating agents
Stem Cell Transplant for Severe Aplastic Anemia
This trial is for people with severe aplastic anemia, myelodysplastic syndrome, or paroxysmal nocturnal hemoglobinuria who want to receive a stem cell transplant using peripheral blood stem cells from a family member.
Flavonoid
Quercetin for Squamous Cell Cancer in Fanconi Anemia
This trial is testing whether the supplement quercetin can prevent or delay the development of skin cancer in people with Fanconi anemia, a rare disease that leads to bone marrow failure and a higher risk for certain cancers.
Thrombopoietin Receptor Agonist
Eltrombopag for Fanconi Anemia
This trial is testing a new drug, eltrombopag, to see if it is effective in people with Fanconi anemia. People with the disease often have reduced blood cell counts and may need transfusions. The trial will monitor participants closely for side effects.
Thrombopoietin Receptor Agonist
Eltrombopag for Aplastic Anemia
This trial is a phase II, open label study of eltrombopag given orally to pediatric patients with previously untreated or relapsed/refractory severe aplastic anemia or recurrent aplastic anemia. The study will have four periods: Screening, Treatment, Follow-up, and Long-term Follow-up.
Monoclonal Antibodies
Stem Cell Transplant + JSP191 for Fanconi Anemia
This trial is testing an experimental cell therapy for Fanconi Anemia which may enable enhanced donor hematopoietic and immune reconstitution with decreased toxicity by transplanting depleted stem cells from a donor after using an experimental treatment called JSP-191 as a part of conditioning.
Popular Filters
Trials for Myelodysplastic Syndrome Patients
Protein Therapeutics
Luspatercept vs Epoetin Alfa for MDS-related Anemia
This trial will compare luspatercept to epoetin alfa to see if luspatercept is more effective in increasing hemoglobin and reducing the need for RBC transfusions in patients with anemia due to MDS.
Trials for Sickle Cell Disease Patients
Cell Therapy
Stem Cell Transplant for Sickle Cell Anemia
This trial tests a new bone marrow transplant method for adults with sickle cell disease and Beta-thalassemia. It uses stem cells from a half-matched family donor, low-dose radiation, and immunosuppressant drugs, but no chemotherapy. The goal is to reduce complications and improve outcomes for patients who lack fully matched donors.
Radiation
Low-Dose Radiation + Immunosuppressants for Sickle Cell Disease
This trial is exploring whether a bone marrow transplant procedure that uses a low dose of radiation and two immunosuppressive drugs is safe for people who are typically excluded from the procedure because of their age.
Cell Therapy
Bone Marrow Transplant for Sickle Cell Disease
This trial uses stem cells from mismatched donors with certain immune cells removed to treat patients with severe blood disorders who lack a perfect donor match. The approach aims to replace damaged cells, reduce complications, and support recovery with additional immune cells. A new technique has been developed to improve the treatment process.
Chemotherapy
INCB000928 + Ruxolitinib for Myelofibrosis
This trial is testing a new drug called INCB000928, either alone or with ruxolitinib, to see if it is safe and effective. It targets people with Myelofibrosis who need regular blood transfusions or have severe anemia. The goal is to see if the drug can reduce the need for transfusions and improve anemia symptoms.
Carbon Dioxide for Sickle Cell Anemia
This trial is looking at how blood flow and metabolism affects brain development in early life. SCA participants and healthy controls will have their blood flow and metabolism examined using MRI, and will also undergo cognitive assessments and brief questionnaires.
Phase 3 Trials
Protein Therapeutics
Luspatercept vs Epoetin Alfa for MDS-related Anemia
This trial will compare luspatercept to epoetin alfa to see if luspatercept is more effective in increasing hemoglobin and reducing the need for RBC transfusions in patients with anemia due to MDS.
Monoclonal Antibodies
M281 for Autoimmune Hemolytic Anemia
This trial is testing a medication called nipocalimab to see if it can help people with a blood disorder called warm autoimmune hemolytic anemia. The medication works by stopping the immune system from destroying red blood cells, which can help reduce anemia symptoms.
Iron Replacement Therapy
Intravenous Iron Therapy for Iron Deficiency in Pregnancy
This trial is testing a new intravenous iron replacement drug to see if it is as effective as other formulations of IV iron, with the goal of reducing maternal and neonatal risks.
Trials With No Placebo
Alkylating agents
Haploidentical Bone Marrow Transplant for Aplastic Anemia
This trial is testing a new treatment for severe aplastic anemia, which is a rare and serious form of bone marrow failure. The new treatment is using a haploidentical donor for transplantation, which has good response rates and significantly lower rates of acute and chronic GVHD.
Thrombopoietin Receptor Agonist
Eltrombopag for Aplastic Anemia
This trial is evaluating the safety and effectiveness of eltrombopag, a drug given by mouth, in people with moderate aplastic anemia or bone marrow failure and unilineage cytopenia who need treatment for significantly low blood cell counts.
View More Related Trials
Frequently Asked Questions
Introduction to autoimmune hemolytic anemia
What are the top hospitals conducting autoimmune hemolytic anemia research?
In the realm of clinical trials for autoimmune hemolytic anemia, several hospitals have emerged as leaders in research and treatment. One such institution is Cincinnati Children's Hospital Medical Center located in Cincinnati. This renowned hospital currently has 11 active trials focused on autoimmune hemolytic anemia, showcasing their commitment to finding innovative solutions for this complex condition. While they may not have conducted any previous trials specifically targeting this disease, their dedication to advancing knowledge and improving outcomes is evident.
Another major player in the field is the National Institutes of Health Clinical Center situated in Bethesda. With nine ongoing clinical trials dedicated to autoimmune hemolytic anemia, this prestigious center serves as a hub for cutting-edge research efforts. Like Cincinnati Children's Hospital Medical Center, they too have yet to conduct historical studies on this particular disorder but are actively working towards driving progress.
Moving westward, Washington University School of Medicine located in Saint Louis also contributes significantly to the advancement of understanding and managing autoimmune hemolytic anemia. With five active clinical trials related to this condition and a modest two previously conducted studies since initiating their first trial in 2018; their relatively recent involvement highlights their growing expertise and dedication within the field.
Similarly making strides is Cleveland Clinic based in Cleveland with four ongoing autoimmune hemolytic anemia clinical trials along with prior record participation from conducting two experiments starting only three years ago from now back till 2018.This continuous engagement demonstrates their commitment toward addressing challenges posed by this rare blood disorder.
Lastly,the National Institutes of Health Clinical Center at its other location on Rockville Pike continues contributing substantial efforts through three open investigations regarding autonomous red-blood-cell destruction; adding up progressively together with previously held one milestone experiment which dates back twenty-four years until1997
These leading hospitals signify a collective drive among medical professionals nationwide striving to unlock breakthroughs that could change lives affected by autoimmune hemolytic anemia forever.Although these specific conditions bring unique challenges,this relentless pursuit of knowledge and innovation promises a brighter future for patients afflicted by rare diseases.
Which are the best cities for autoimmune hemolytic anemia clinical trials?
When it comes to clinical trials for autoimmune hemolytic anemia, several cities stand out as hubs of research and innovation. New york, with 19 active trials, is exploring treatments such as Cohort B, Arm B2P: BNT162b2, Nivolumab, and Etavopivat 400 mg QD daily. Cincinnati in Ohio follows closely behind with 18 ongoing studies focused on therapies like Hydroxyurea and Quercetin. Los Angeles in California also has 18 active trials investigating treatments including Fostamatinib disodium and Lenalidomide. These three cities provide individuals battling autoimmune hemolytic anemia access to cutting-edge clinical trials that may offer new hope for improved treatment outcomes.
Which are the top treatments for autoimmune hemolytic anemia being explored in clinical trials?
Exciting developments are taking place in the field of autoimmune hemolytic anemia, as clinical trials explore novel treatments. Taking center stage is rituximab, a promising therapy undergoing active investigation. Another contender gaining attention is eculizumab, showing promise in preliminary studies. Additionally, fostamatinib has piqued researchers' interest with its potential to combat this debilitating condition. As these innovative treatments undergo rigorous testing and evaluation in clinical trials, they offer new hope for patients suffering from autoimmune hemolytic anemia.
What are the most recent clinical trials for autoimmune hemolytic anemia?
Exciting advancements in clinical trials offer hope for individuals with autoimmune hemolytic anemia. Daprodustat, currently in Phase 3, has emerged as a potential treatment option that holds promise for managing this condition. Additionally, Panzyga IVIG is being investigated in Phase 2 trials to evaluate its efficacy against autoimmune hemolytic anemia. Another experimental drug called -Bitopertin is undergoing combined Phase 1 and Phase 2 studies to assess its effectiveness. Moreover, FP-045 is also being explored through joint Phase 1 and Phase 2 trials as a possible therapy for this condition. Finally, the safety and dose confirmation run-in period (SRP) of Obexelimab in patients with autoimmune hemolytic anemia is underway in Phase 3 investigations. These ongoing efforts pave the way towards improved treatments for those affected by autoimmune hemolytic anemia
What autoimmune hemolytic anemia clinical trials were recently completed?
Recent advancements in clinical trials have shown promising results for the treatment of autoimmune hemolytic anemia. In November 2021, Annexon, Inc. completed a trial investigating ANX005 as a potential therapy option. Another notable study was conducted by Rigel Pharmaceuticals, which concluded in April 2019 and explored the effectiveness of Fostamatinib disodium. Additionally, Apellis Pharmaceuticals' APL-2 trial ended in August 2017 and showcased encouraging outcomes. These recent research efforts provide hope for individuals affected by this challenging condition and demonstrate the ongoing commitment to finding effective treatments for autoimmune hemolytic anemia.